Medicare Archives -

The US Centres for Medicare and Medicaid Services (CMS) has firmed up its draft decision to limit reimbursement

CMS decision on Aduhelm is in, and it’s bad news for Biogen

https://pharmaphorum.com/news/cms-decision-on-aduhelm-is-in-and-its-bad-news-for-biogen/

Market Access/ News/ News

Eisai bites back against restricted coverage plan for Aduhelm

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, Eisai, Medicare, neurology, reimbursement 0 Comment

Japanese drugmaker Eisai has published comments filed with the US Centers for Medicare & Medicaid Services over its

Eisai bites back against restricted coverage plan for Aduhelm

https://pharmaphorum.com/news/eisai-bites-back-against-restricted-coverage-plan-for-aduhelm/

Market Access/ News/ News

Lilly defers Alzheimer’s drug filing after CMS’ ‘disappointing’ decision

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, donanemab, Eli Lilly, Medicare, neurology, reimbursement 0 Comment

Eli Lilly has backed away from plans to file Alzheimer’s drug donanemab in the first quarter of this

Lilly defers Alzheimer’s drug filing after CMS’ ‘disappointing’ decision

https://pharmaphorum.com/news/lilly-defers-alzheimers-drug-filing-after-cms-disappointing-decision/

News/ News/ Sales and Marketing

Medicare limits Aduhelm coverage to clinical trial participants

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, Eisai, Medicare, reimbursement 0 Comment

Biogen’s difficult launch of controversial Alzheimer’s therapy Aduhelm has been made even harder by a proposal by Medicare

Medicare limits Aduhelm coverage to clinical trial participants

https://pharmaphorum.com/news/medicare-limits-aduhelm-coverage-to-clinical-trial-participants/

News/ News/ Sales and Marketing

Biogen takes axe to Aduhelm price in a bid to drive take-up

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, Drug pricing, Medicare, neurology 0 Comment

Biogen has cut the list price of its Alzheimer’s disease therapy in half from $56,000 to $28,200 a

Biogen takes axe to Aduhelm price in a bid to drive take-up

https://pharmaphorum.com/news/biogen-takes-axe-to-aduhelm-price-in-a-bid-to-drive-take-up/

Tablets on dollar bills (treatment, addiction, aging - concept).

News/ News/ Sales and Marketing

Democrats agree last-ditch deal to save drug pricing plans

Phil Taylor Drug pricing, Financial, Joe Biden, Medicare, PhRMA, US 0 Comment

Under fire for abandoning a plan to allow Medicare to negotiate drug pricing, Democrats in the Senate have

Democrats agree last-ditch deal to save drug pricing plans

https://pharmaphorum.com/news/democrats-agree-last-ditch-deal-to-save-drug-pricing-plans/

Digital/ News/ News

US telemedicine company owner charged with $784m fraud

Phil Taylor fraud, Medicare, telemedicine 0 Comment

A jury in the US has charged a Florida man who owns multiple telemedicine companies in connection with

US telemedicine company owner charged with $784m fraud

https://pharmaphorum.com/news/us-telemedicine-company-owner-charged-with-784m-fraud/

Market Access/ News/ News

US starts review of Aduhelm coverage amid fears of Medicare hit

Phil Taylor Alzheimer's disease, Biogen, central nervous system, Eisai, Medicare, neurology, pricing 0 Comment

The US government has started a review of how Biogen and Eisai’s pricey new Alzheimer’s disease therapy Aduhelm

US starts review of Aduhelm coverage amid fears of Medicare hit

https://pharmaphorum.com/news/us-starts-review-of-aduhelm-coverage-amid-fears-of-medicare-hit/

Market Access/ Views & Analysis/ Views and analysis

Biden administration – What can the healthcare industry expect?

Catherine Longworth Biden, COVID-19, healthcare policy, Life Sciences, Medicare, usa 0 Comment

As Joe Biden takes the reins at the White House, pharmaphorum asks experts how his presidential tenure may

Biden administration – What can the healthcare industry expect?

https://pharmaphorum.com/views-and-analysis/biden-administration-what-can-the-healthcare-industry-expect/

Trending

Medicare

Login